Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies.
LaNova Medicines has begun a Phase 1 clinical trial in China for LM-299, a bispecific antibody targeting PD-1 and VEGF, in patients with advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.